CD274 and colorectal cancer: Here we report the clinical results from the first study, to our knowledge, to target micrometastatic colorectal cancer, informed by detection of ctDNA as a surrogate for minimal residual disease, by concomitant targeting of TGFβ signaling and PD-L1 blockade in patients with liver-limited mCRC.